Selection of 7 products from
Ā£42.49 to Ā£55.49
Comfortis tablets are given once a month to control fleas on dogs and cats. The drug is lethal to blood sucking insects but has little or no effect on dogs. (Occasionally dogs will vomit after taking a tablet.) It is best to give Comfortis with food. This reduces the chances of vomiting as well as enabling a more persistent flea-killing effect afterwards, so that one tablet will last for the whole month. Comfrotis tablets come in five different sizes to suit dogs of different body weights and two sizes for cats. Comfortis is not recommended for dogs under 14 weeks of age, or less than 3.9kg bodyweight.
See below the list of products for the Dosage information for dogs and cats.
All prices include VAT where applicable.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Each tablet contains:
Active substance:
Comfortis 90 mg spinosad 90 mg
Comfortis 140 mg spinosad 140 mg
Comfortis 180 mg spinosad 180 mg
Comfortis 270 mg spinosad 270 mg
Comfortis 425 mg spinosad 425 mg
Comfortis 665 mg spinosad 665 mg
Comfortis 1040 mg spinosad 1040 mg
Comfortis 1620 mg spinosad 1620 mg
For the full list of excipients, see Pharmaceutical particulars section
Chewable tablets
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
140 mg: 4222
425 mg: 4229
1040 mg: 4231
1620 mg: 4227
Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
90 mg: 4221
270 mg: 4223
665 mg: 4230
Tan to brown, or speckled with embedded darker particles, round, flat, bevelled edge tablets plain on one side and debossed with a number and a line above on the other side:
180 mg: 4228
Target species
Dogs and cats.
Indications for use, specifying the target species
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Contraindications
Do not use in dogs or cats under 14 weeks of age.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
All dogs and cats within the household should be treated.
Fleas from pets often infest the animalās basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleasā life cycle and may be needed to control the flea population in contaminated households.
Special precautions for use
Special precautions for use in animals
Use with caution in dogs and cats with pre-existing epilepsy.
Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
The recommended dosage regimen should be followed (see overdose section).
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Accidental ingestion may cause adverse reactions.
Children should not come into contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Dogs
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45ā70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.
Cats
In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours afterdosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50ā75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.
The frequency of adverse reactions is defined using the following convention:
Use during pregnancy, lactation or lay
Pregnancy:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.
Lactation:
In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Fertility:
Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
The safety of the product in male dogs and male cats used for breeding has not been determined.
Interaction with other medicinal products and other forms of interaction
Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
Post marketing reports, following the concomitant use of Comfortis with āoff labelā high dose ivermectin indicate that dogs have experienced trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Amounts to be administered and administration route
For oral use.
The veterinary medicinal product should be administered with food or immediately after feeding.
Dogs:
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 45-70 mg/kg bodyweight for dogs:
| Dog bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.3-2 | 1 x 90 mg tablet |
| 2.1-3 | 1 x 140 mg tablet |
| 3.1-3.8 | 1 x 180 mg tablet |
| 3.9-6 | 1 x 270mg tablet |
| 6.1-9.4 | 1 x 425 mg tablet |
| 9.5-14.7 | 1 x 665 mg tablet |
| 14.8-23.1 | 1 x 1040 mg tablet |
| 23.2-36 | 1 x 1620 mg tablet |
| 36.1-50.7 | 1 x 1620 mg tablet + 1 x 665 mg tablet |
| 50.8-72 | 2 x 1620 mg tablets |
Cats:
The Veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 50-75 mg/kg bodyweight for cats:
| Cat bodyweight (kg) | No. of tablets & strength (mg spinosad) |
|---|---|
| 1.2-1.8 | 1 x 90 mg tablets |
| 1.9-2.8 | 1 x 140 mg tablet |
| 2.9-3.6 | 1 x 180 mg tablet |
| 3.7-5.4 | 1 x 270 mg tablet |
| 5.5-8.5* | 1 x 425 mg tablet |
| *Cats over 8.5 kg: give the appropriate combination of tablets |
Comfortis tablets are chewable and palatable for dogs. If the dog or cat does not accept the tablets directly they may be administered with food, or directly by opening the animalās mouth and placing the tablet onto the back of the tongue.
If vomiting occurs within an hour of administration and the tablet is visible, re-dose the animal with another full dose to ensure maximum effectiveness of the product.
If a dose is missed, administer the veterinary medicinal product with the next offering of food and resume a monthly dosing schedule.
The veterinary medicinal product may safely be given at monthly intervals at the recommended dose.
The residual insecticidal properties of the product persist for up to 4 weeks after a single administration. If fleas reappear in the fourth week, the treatment interval can be shortened by up to 3 days in dogs. In cats, the full 4 week gap between treatments should be maintained, even if fleas reappear before the end of the 4 weeks.
Seek veterinary advice regarding information on the optimal time to start treatment with this product.
Overdose (symptoms, emergency procedures, antidotes), if necessary
There is no antidote available. In case of adverse clinical signs, the animal should be treated symptomatically.
Dogs:
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose. Vomiting is most likely caused by a local effect on the small intestines. At doses in excess of the recommended dose vomiting becomes a very common event. At doses of approximately 2.5 times the recommended dose, spinosad caused vomiting in the vast majority of dogs.
At doses up to 100 mg/kg bodyweight per day for 10 days, the only clinical symptom of overdose was vomiting, which occurred usually within 2.5 hours of dosing. Mild elevations of ALT (alanine aminotransferase) occurred in all dogs treated with Comfortis, although values returned to their baseline by day 24. Phospholipidosis (vacuolation of lymphoid tissues) also occurred; although this was not related to clinical signs in dogs treated up to 6 months.
Cats:
After a single acute overdose corresponding to 1.6 times the maximum label dose, spinosad caused vomiting in approximately half of the cats, and depression, pacing/panting and severe diarrhoea on rare occasions.
At doses of 75 to 100 mg/kg bodyweight per day for 5 days, given at monthly intervals for a period of six months, the most commonly observed clinical sign was vomiting. Furthermore, a reduction of food intake was observed in females, however a significant reduction in their bodyweight was not observed.
Phospholipidosis (vacuolation of the cells of the liver, adrenal gland and lung) also occurred. Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights. However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Withdrawal period
Not applicable.
Pharmacotherapeutic group: other ectoparasiticides for systemic use.
ATCvet code: QP53BX03.
Pharmacodynamic properties
Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.
The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.
Insecticidal activity against new infestations persists for up to 4 weeks.
Pharmacokinetic particulars
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
In dogs, spinosyns A and D are rapidly absorbed and extensively distributed after oral administration.
Bioavailability was shown to be approximately 70%. The mean Tmax for spinosyns A and D ranged from 2ā4 hours and the mean elimination half-life ranged from 127.5 to 162.6 hours and 101.3 to 131.9 hours respectively. AUC and Cmax values were higher in fed than fasted dogs and increased approximately linearly with increasing dose-rates over the intended therapeutic dose range. Therefore, it is recommended to treat dogs with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and Ndemethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in dogs. In lactating bitches, spinosad is excreted in the colostrum/milk.
In cats, spinosyns A and D are equally rapidly absorbed and extensively distributed after oral administration. Plasma protein binding is high (~99%). Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4ā12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight. AUC and Cmax values were higher in fed than fasted cats.
Therefore, it is recommended to treat cats with food as this maximises the opportunity for fleas to ingest lethal amounts of spinosad. In adult cats, the AUC increased over 3 consecutive months of dosing with 75 mg spinosad/kg bodyweight, after which steady state was achieved; however, no clinical impact occurred as a result of this.
The primary faecal and urinary metabolites in both the rat and the cat were identified as the glutathione conjugates of the parent compounds and N-demethylated spinosyns A and D. Excretion is primarily via the faeces, and also to a lesser extent in the urine. Faecal excretion accounted for the vast majority of metabolites in cats.
List of excipients
Microcrystalline cellulose
Artificial beef flavour
Hydroxypropylcellulose
Colloidal silicon, anhydrous
Croscarmellose sodium
Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Special precautions for storage
Keep the blister in the outer carton to protect from light.
Nature and composition of immediate packaging
Clear PCTFE/PE/PVC blister sealed with aluminium foil containing 3 or 6 chewable tablets in cardboard box.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
NA
EU/2/10/115/016 (90 mg, 3 tablets)
EU/2/10/115/017 (90 mg, 6 tablets)
EU/2/10/115/018 (140 mg, 3 tablets)
EU/2/10/115/019 (140 mg, 6 tablets)
EU/2/10/115/020 (180 mg, 3 tablets)
EU/2/10/115/021 (180 mg, 6 tablets)
EU/2/10/115/011 (270 mg, 3 tablets)
EU/2/10/115/001 (270 mg, 6 tablets)
EU/2/10/115/012 (425 mg, 3 tablets)
EU/2/10/115/003 (425 mg, 6 tablets)
EU/2/10/115/013 (665 mg, 3 tablets)
EU/2/10/115/005 (665 mg, 6 tablets)
EU/2/10/115/014 (1040 mg, 3 tablets)
EU/2/10/115/007 (1040 mg, 6 tablets)
EU/2/10/115/015 (1620 mg, 3 tablets)
EU/2/10/115/009 (1620 mg, 6 tablets)
11/02/2011.
Nil.
Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.
For UK delivery, we charge the following:
| Order Total | Weight | Delivery |
| £0-Ā£28.99 | Under 2kg | Ā£2.99 |
| 2kg+ | Ā£4.99 | |
| £29-Ā£38.99 | Under 2kg | Free |
| 2kg+ | Ā£4.99 | |
| £39+ | Under 2kg | Free |
| 2kg+ | Free |
Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.
For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.
We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of Ā£10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.
Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.
Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a Ā£1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the Ā£1.99 once per order, regardless of how many temperature controlled items you purchase in that order.
Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.
To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.
*For full details on returns, see our terms and conditions page.
Below are some recent questions we've received regarding Comfortis Chewable Flea Tablets, including answers from our team.
becky
My dog was sick 4 hours after takeing comfortis.will it still work.
The active ingredient should have been absorbed in less time than 4 hours so I it likely to be fully effective. Not possible to guarantee, but should be OK. (It is always best to give this tablet with food to help reduce the chances of vomiting and to increase the effect. )
Ian
I have a prescription for 9 tablets but the packs come in 6, can I order 9 tablets.
Sorry but we do not split packs, so have to sell them in multiples of 6. If we send just 6 now, then the remaining 3 would remain on your "allowed list" until you need them, but you would need another prescription to go with it.
